Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta …

The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the
mandate of the World Health Organization (WHO) to support countries in the reinforcement …

Abstract In December 2022 World Health Organization released a new treatment for
multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main …

Background Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most
common form of drug resistance, and is associated with failure, relapse, and acquired …

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it
relies on second-line drugs that are less potent and more toxic than those used in the …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

In the last decade, multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at
least isoniazid and rifampicin) has become an epidemiological issue of first priority at the …

We sought to compare the effectiveness of two World Health Organization (WHO)-
recommended regimens for the treatment of rifampin-or multidrug-resistant (RR/MDR) …

Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To
evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a …